%0 Journal Article %A Yao Hu %A Adrienne M. Stilp %A Caitlin P. McHugh %A Deepti Jain %A Xiuwen Zheng %A John Lane %A Shuquan Rao %A Sébastian Méric de Bellefon %A Laura M. Raffield %A Ming-Huei Chen %A Lisa R. Yanek %A Marsha Wheeler %A Jai Broome %A Jee-Young Moon %A Paul S. de Vries %A Brian D. Hobbs %A Quan Sun %A Praveen Surendran %A Jennifer A. Brody %A Thomas W. Blackwell %A Hélène Choquet %A Kathleen Ryan %A Ravindranath Duggirala %A Nancy Heard-Costa %A Zhe Wang %A Nathalie Chami %A Michael H. Preuss %A Nancy Min %A Lynette Ekunwe %A Leslie A. Lange %A Mary Cushman %A Nauder Faraday %A Joanne E. Curran %A Laura Almasy %A Kousik Kundu %A Albert V. Smith %A Stacey Gabriel %A Jerome I. Rotter %A Myriam Fornage %A Donald M. Lloyd-Jones %A Ramachandran S. Vasan %A Nicholas L. Smith %A Kari E. North %A Eric Boerwinkle %A Lewis C. Becker %A Joshua P. Lewis %A Goncalo R. Abecasis %A Lifang Hou %A Jeffrey R. O’Connell %A Alanna C. Morrison %A Terri H. Beaty %A Robert Kaplan %A Adolfo Correa %A John Blangero %A Eric Jorgenson %A Bruce M. Psaty %A Charles Kooperberg %A Hua Tang %A Ruth J.F. Loos %A Nicole Soranzo %A Adam S. Butterworth %A Debbie Nickerson %A Stephen S. Rich %A Braxton D. Mitchell %A Andrew D. Johnson %A Paul L. Auer %A Yun Li %A Rasika A. Mathias %A Guillaume Lettre %A Daniel E. Bauer %A Nathan Pankratz %A Cathy C. Laurie %A Cecelia A. Laurie %A Matthew P. Conomos %A Alexander P. Reiner %A the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium %T Whole genome sequencing association analysis of quantitative red blood cell phenotypes: the NHLBI TOPMed program %D 2020 %R 10.1101/2020.12.09.20246736 %J medRxiv %P 2020.12.09.20246736 %X Whole genome sequencing (WGS), a powerful tool for detecting novel coding and non-coding disease-causing variants, has largely been applied to clinical diagnosis of inherited disorders. Here we leveraged WGS data in up to 62,653 ethnically diverse participants from the NHLBI Trans-Omics for Precision Medicine (TOPMed) program and assessed statistical association of variants with seven red blood cell (RBC) quantitative traits. We discovered 14 single variant-RBC trait associations at 12 genomic loci. Several of the RBC trait-variant associations (RPN1, ELL2, MIDN, HBB, HBA1, PIEZO1, G6PD) were replicated in independent GWAS datasets imputed to the TOPMed reference panel. Most of these newly discovered variants are rare/low frequency, and several are observed disproportionately among non-European Ancestry (African, Hispanic/Latino, or East Asian) populations. We identified a 3bp indel p.Lys2169del (common only in the Ashkenazi Jewish population) of PIEZO1, a gene responsible for the Mendelian red cell disorder hereditary xerocytosis [OMIM 194380], associated with higher MCHC. Stepwise conditional analysis identified 12 independent red cell trait-associated variants in the chromosome 11 region spanning the beta-globin genes. In gene-based rare variant aggregated association analysis, seven genes (HBA1/HBA2, HBB, TMPRSS6, G6PD, CD36, TFRC and SLC12A7) were associated with RBC traits, independently of known single variants. Several of the variants in HBB, HBA1, TMPRSS6, and G6PD represent the carrier state for known coding, promoter, or splice site loss-of-function variants that cause inherited RBC disorders. Together, these results demonstrate the utility of WGS in ethnically-diverse population-based samples for expanding knowledge of the genetic architecture of quantitative hematologic traits and suggest a continuum between complex trait and Mendelian red cell disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCore support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study protocols for the Amish study were approved by the institutional review board at the University of Maryland Baltimore. Informed consent was obtained from each study participant. The BioMe cohort was approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai. All BioMe participants provided written, informed consent for genomic data sharing. All CARDIA participants provided informed consent, and the study was approved by the Institutional Review Boards of the University of Alabama at Birmingham and the University of Texas Health Science Center at Houston. All CHS participants provided informed consent, and the study was approved by the Institutional Review Board [or ethics review committee] of University Washington. All COPDGene participants provided written informed consent, and the study was approved by the Institutional Review Boards of the participating clinical centers. The Framingham Heart Study was approved by the Institutional Review Board of the Boston University Medical Center. All study participants provided written informed consent. All participants of GeneSTAR provided written informed consent and the study was approved by the Johns Hopkins Medicine Institutional Review Board. HCHS/SOL was approved by the institutional review boards (IRBs) at each field center, where all participants gave written informed consent, and by the Non-Biomedical IRB at the University of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All IRBs approving the study are: Non-Biomedical IRB at the University of North Carolina at Chapel Hill. Chapel Hill, NC; Einstein IRB at the Albert Einstein College of Medicine of Yeshiva University. Bronx, NY; IRB at Office for the Protection of Research Subjects (OPRS), University of Illinois at Chicago. Chicago, IL; Human Subject Research Office, University of Miami. Miami, FL; Institutional Review Board of San Diego State University. San Diego, CA. The JHS study was approved by Jackson State University, Tougaloo College, and the University of Mississippi Medical Center IRBs, and all participants provided written informed consent. All MESA participants provided written informed consent, and the study was approved by the Institutional Review Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. All SAFS participants provided informed consent, and the study was approved by Institutional Review Board at the University of Texas Rio Grande Valley. All WHI participants provided informed consent and the study was approved by the Institutional Review Board (IRB) of the Fred Hutchinson Cancer Research Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from TOPMed are available via dbGaP. %U https://www.medrxiv.org/content/medrxiv/early/2020/12/11/2020.12.09.20246736.full.pdf